Fibroblast growth factor signaling: a new therapeutic opportunity in cancer
Cet article passe en revue les perspectives offertes par le ciblage de la voie de signalisation du facteur de croissance des fibroblastes pour le traitement des cancers
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays an important role in normal organ, vascular and skeletal development. Deregulation of FGFR signaling through genetic modification or over-expression of the receptors (or their ligands) has been observed in numerous tumor settings, whilst the FGF/FGFR axis also plays a key role in driving tumor angiogenesis. A growing body of preclinical data demonstrates that inhibition of FGFR signaling can result in antiproliferative and/or pro-apoptotic effects, both in vitro and in vivo, thus confirming the validity of the FGF/FGFR axis as a potential therapeutic target. In the past, development of therapeutic approaches to target this axis has been hampered by our inability to develop FGFR selective agents. With the advent of a number of new modalities for selectively inhibiting FGF/FGFR signaling, we are now in a unique position to test and validate clinically the many hypotheses that have been generated preclinically.